Seth Gordon
General Manager
Expertise:
Seth’s deep understanding of the healthcare industry comes from more than 30 years of experience on both sides of the industry––pharmaceuticals and agency work.
He has extensive product marketing and launch experience on both the U.S. and global side. His knowledge of market-access reinforces and informs EVERSANA’s value-based care and patient-centric approach.
Seth holds a master’s degree in business administration from Columbia University and a bachelor’s degree from Skidmore College.
Articles by Seth Gordon
WEBINAR: Reimagining the Patient Journey for CGTs: Informing, Engaging and Empowering the Patient Population
Cell and gene therapies (CGTs) hold great life-saving and therapeutic advancement potential, but their complexity requires careful approach–starting with engaging and educating patient communities earlier. While the patient’s voice should be a guiding force throughout the drug development process, it is also critical for those in drug development to participate in educating about these novel treatment approaches to facilitate empowered patient decision-making about their own healthcare. To set the stage for future success, we need to reimagine how patient education and engagement are introduced to the patient journey. How do we ensure all key stakeholders have access to tailored education around a potentially, revolutionary new kind of treatment? In this […]
The Power of Working Together With the Rare Disease Community
“Alone, we can do so little; together, we can do so much.” – Helen Keller This sentiment addresses the power of working together to improve health in rare disease. At EVERSANA, we have developed a unique working relationship with rare disease communities. Successfully working with these communities, especially in gene therapy, requires a demonstrated long-term commitment to the science and commitment to a cure. These communities are central to the health of these patients and their families. Download the latest article of EVERSANA ENGAGE’s General Manager, Seth Gordon, to learn how to drive success with a gene therapy launch.
Clinical Pathways and Policy to Guard Against Misaligned Incentives
The application of clinical pathways and their enforcement through quality metric benchmark setting and appropriate use criteria is needed to guard against perverse financial incentives that encourage overutilization and underutilization. Moving forward, the more diligent payers and integrated delivery networks can be in evaluating and incorporating utilization criteria when establishing clinical pathways, the better off our system will be. Our experts explore different payer policies and market dynamics that can result in the overutilization or underutilization of healthcare treatments. They also explore opportunities to mitigate the unintended consequences of previous policies, both through new Centers for Medicare & Medicaid Services (CMS) policy efforts and clinical pathway application. Because most spending […]